Woodstock Corp Boosts Holdings in Amgen Inc. (NASDAQ:AMGN)

Woodstock Corp increased its position in Amgen Inc. (NASDAQ:AMGN) by 0.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,934 shares of the medical research company’s stock after purchasing an additional 89 shares during the quarter. Woodstock Corp’s holdings in Amgen were worth $4,812,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Patriot Investment Management Group Inc. boosted its stake in shares of Amgen by 4.4% during the 3rd quarter. Patriot Investment Management Group Inc. now owns 5,305 shares of the medical research company’s stock valued at $1,709,000 after buying an additional 223 shares during the last quarter. Thomasville National Bank raised its holdings in Amgen by 1.8% in the third quarter. Thomasville National Bank now owns 3,447 shares of the medical research company’s stock valued at $1,111,000 after acquiring an additional 60 shares in the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new position in Amgen during the 3rd quarter valued at $234,000. Redhawk Wealth Advisors Inc. grew its holdings in Amgen by 3.9% during the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 2,569 shares of the medical research company’s stock worth $828,000 after acquiring an additional 96 shares in the last quarter. Finally, Selway Asset Management increased its position in shares of Amgen by 0.4% in the 3rd quarter. Selway Asset Management now owns 14,267 shares of the medical research company’s stock worth $4,597,000 after purchasing an additional 50 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN opened at $328.35 on Monday. Amgen Inc. has a one year low of $249.70 and a one year high of $346.85. The company has a 50-day moving average of $326.06 and a two-hundred day moving average of $310.92. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The stock has a market cap of $176.14 billion, a price-to-earnings ratio of 46.91, a PEG ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. Amgen’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period last year, the firm earned $5.00 earnings per share. On average, equities research analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.74%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio is currently 128.57%.

Analyst Ratings Changes

A number of research firms recently commented on AMGN. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a research note on Wednesday, September 25th. Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and boosted their price target for the company from $320.00 to $333.00 in a report on Monday. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $380.00 price target (up from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average price target of $326.95.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.